Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series. Issue 4 (July 2016)
- Record Type:
- Journal Article
- Title:
- Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series. Issue 4 (July 2016)
- Main Title:
- Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients
- Authors:
- Roncero, Carlos
Ros-Cucurull, Elena
Grau-López, Lara
Fadeuilhe, Christian
Casas, Miguel - Abstract:
- Abstract : Objectives: Episodes of psychotic agitation are frequent in patients with dual diagnosis, that is, in patients with concomitant psychiatric and substance use disorders. Rapid intervention is needed to treat the agitation at a mild stage to prevent the escalation to aggressive behavior. Inhaled loxapine has been demonstrated to rapidly improve symptoms of mild-to-moderate agitation in adults with psychiatric disorders (schizophrenia and bipolar disorder), but data on patients with dual diagnosis are scarce. Methods: This study is a retrospective review of data from a case series of patients with dual diagnosis, which were attended for symptoms of agitation while at the emergency room (n = 9), in the outpatient clinic (n = 4), or during hospitalization (n = 1) at 1 center in Spain. All patients received inhaled loxapine for treating the agitation episodes. Results: Data from 14 patients with dual diagnosis were reviewed. All patients had 1 or more psychiatric disorders (schizophrenia, bipolar I disorder, drug-induced psychotic disorder, posttraumatic stress, borderline or antisocial personality disorder, depression, or anxiety) along with a variety of substance use disorders (alcohol, cocaine, cannabis, amphetamines, hypnotics and antianxiety drugs, caffeine, or street drugs). Overall, only 1 dose of inhaled loxapine (9.1 mg) was needed to calm each patient during an acute episode of agitation. Conclusions: Inhaled loxapine was rapid, effective, and well accepted inAbstract : Objectives: Episodes of psychotic agitation are frequent in patients with dual diagnosis, that is, in patients with concomitant psychiatric and substance use disorders. Rapid intervention is needed to treat the agitation at a mild stage to prevent the escalation to aggressive behavior. Inhaled loxapine has been demonstrated to rapidly improve symptoms of mild-to-moderate agitation in adults with psychiatric disorders (schizophrenia and bipolar disorder), but data on patients with dual diagnosis are scarce. Methods: This study is a retrospective review of data from a case series of patients with dual diagnosis, which were attended for symptoms of agitation while at the emergency room (n = 9), in the outpatient clinic (n = 4), or during hospitalization (n = 1) at 1 center in Spain. All patients received inhaled loxapine for treating the agitation episodes. Results: Data from 14 patients with dual diagnosis were reviewed. All patients had 1 or more psychiatric disorders (schizophrenia, bipolar I disorder, drug-induced psychotic disorder, posttraumatic stress, borderline or antisocial personality disorder, depression, or anxiety) along with a variety of substance use disorders (alcohol, cocaine, cannabis, amphetamines, hypnotics and antianxiety drugs, caffeine, or street drugs). Overall, only 1 dose of inhaled loxapine (9.1 mg) was needed to calm each patient during an acute episode of agitation. Conclusions: Inhaled loxapine was rapid, effective, and well accepted in all dual-pathology patients presenting with acute agitation in the emergency setting. Inhaled loxapine facilitated both patient cooperation and an adequate management of his or her disease. … (more)
- Is Part Of:
- Clinical neuropharmacology. Volume 39:Issue 4(2016)
- Journal:
- Clinical neuropharmacology
- Issue:
- Volume 39:Issue 4(2016)
- Issue Display:
- Volume 39, Issue 4 (2016)
- Year:
- 2016
- Volume:
- 39
- Issue:
- 4
- Issue Sort Value:
- 2016-0039-0004-0000
- Page Start:
- Page End:
- Publication Date:
- 2016-07
- Subjects:
- agitation -- inhaled loxapine -- dual diagnosis -- substance use disorders -- mental disorders
Neuropharmacology -- Periodicals
615.78 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00002826-000000000-00000 ↗
http://journals.lww.com/clinicalneuropharm/pages/default.aspx ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/WNF.0000000000000153 ↗
- Languages:
- English
- ISSNs:
- 0362-5664
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.310600
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 2020.xml